FF Stock Overview
Fine Foods & Pharmaceuticals N.T.M. S.p.A. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
Fine Foods & Pharmaceuticals N.T.M. S.p.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €8.10 |
52 Week High | €9.62 |
52 Week Low | €7.70 |
Beta | 0.68 |
11 Month Change | -3.57% |
3 Month Change | -1.94% |
1 Year Change | 1.25% |
33 Year Change | -48.73% |
5 Year Change | -27.68% |
Change since IPO | -16.06% |
Recent News & Updates
Recent updates
Solid Earnings Reflect Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Strength As A Business
Sep 20Is There An Opportunity With Fine Foods & Pharmaceuticals N.T.M. S.p.A.'s (BIT:FF) 40% Undervaluation?
Apr 28Estimating The Fair Value Of Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF)
Mar 20Something To Consider Before Buying Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) For The 1.1% Dividend
Feb 22A Look At Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Share Price Returns
Feb 01What You Need To Know About Fine Foods & Pharmaceuticals N.T.M. S.p.A.'s (BIT:FF) Investor Composition
Jan 14We Wouldn't Rely On Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Statutory Earnings As A Guide
Dec 28Is Fine Foods & Pharmaceuticals N.T.M (BIT:FF) Using Too Much Debt?
Dec 08Shareholder Returns
FF | IT Life Sciences | IT Market | |
---|---|---|---|
7D | -1.2% | -5.2% | 0.9% |
1Y | 1.3% | 2.8% | 14.5% |
Return vs Industry: FF underperformed the Italian Life Sciences industry which returned 2.8% over the past year.
Return vs Market: FF underperformed the Italian Market which returned 14.5% over the past year.
Price Volatility
FF volatility | |
---|---|
FF Average Weekly Movement | 3.6% |
Life Sciences Industry Average Movement | 5.9% |
Market Average Movement | 4.2% |
10% most volatile stocks in IT Market | 7.2% |
10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: FF has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: FF's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1984 | 780 | Marco Francesco Eigenmann | www.finefoods.it |
Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract development and manufacturing of drugs, food supplements, and other nutraceutical products and medical devices for the pharmaceutical and nutraceutical industries. It offers pharmaceutical products, including powders, soluble, effervescent and chewable granules, filmed and effervescent tablets, fast melting/sublingual tablets, film-coated tablets, and hard gelatine capsules in various types of packaging, such as sachets, sticks, pillboxes, jars, blisters, tubes, and strips for various therapeutic areas, such as probiotics, multivitamins and minerals, immune systems, sleep and relax, gastrointestinal system, circulatory system, osteoarticular system, urinary system, women health, beauty, healthy ageing, and mental wellbeing. In addition, the company is involved in the production, marketing, research, and development of cosmetics products comprising liquid detergents for personal hygiene, hair care, skin care, bath and shower gels, shampoo and conditioners, shaping waxes, mouthwash and breath products, creams, gel and toothpaste, roll-on, stick and vapo spray deodrants, intimate cleansers, emulsions and microemulsions, gels, liquid soaps, skin care emulsions, oral hygiene, deodorants, and alcohol-based perfumery products in packaging, including coextruded and laminated tubes, aluminium tubes, special packs, lip sticks, air less, and various bottles and jars under its own and third-party brands.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. Fundamentals Summary
FF fundamental statistics | |
---|---|
Market cap | €198.31m |
Earnings (TTM) | €4.85m |
Revenue (TTM) | €244.09m |
40.9x
P/E Ratio0.8x
P/S RatioIs FF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FF income statement (TTM) | |
---|---|
Revenue | €244.09m |
Cost of Revenue | €167.55m |
Gross Profit | €76.54m |
Other Expenses | €71.69m |
Earnings | €4.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.20 |
Gross Margin | 31.36% |
Net Profit Margin | 1.99% |
Debt/Equity Ratio | 43.2% |
How did FF perform over the long term?
See historical performance and comparison